Corep Therapeutics Slumps After Drug Rejection

15 days ago

Isabelle Lee

"You're also looking at some biotechs and and one ticker co. It's not Cortiseps like The Last of Us, but it's what? >> Corep. So, Corsip therapeutics stock is down by almost 50%. That's after regulators rejected the company's drug to treat a form of high blood pressure. So we know that with biotech companies whenever there's a treatment and there's a rejection the stock really plunges. So this is the lowest since at least 2024. I was bracing myself for something more drastic but at least when I go to since s functional bloomberg terminal is just till 2024. So it's the drug that aims to treat patients with hypertension and too much of those hor too much of those hormone cortisol. So the stock is now down."

Corsip Therapeutics is facing a steep decline, down nearly 50% following regulatory rejection of its hypertension drug, highlighting significant near-term risks in the biotech sector.

Related Stocks